Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPX4589 (LM-302) in CLDN18.2-Positive Advanced Solid Tumors
NCT05001516Phase 1Completed
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tpx-4589 in solid tumor (advanced stage) (6 arms), sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Dose limiting toxicity, Number of participants with adverse events and serious adverse events up to 1 year and 4 more. Started Dec 2021; status: completed.
02
Drugs
tpx-4589
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05001516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001516.